Taurine supplementation abates cirrhosis-associated locomotor dysfunction

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Hepatic encephalopathy and hyperammonemia are serious complications of liver cirrhosis.
• Ammonia toxicity targets the brain, causing oxidative stress, cognitive deficits, and locomotor dysfunction.
• Current pharmacological interventions for cirrhosis-associated brain injury are limited.

Purpose of the Study:

• To investigate the neuroprotective effects of taurine (TAU) supplementation.
• To evaluate TAU's impact on locomotor activity disturbances in cirrhosis.
• To assess TAU's influence on oxidative stress markers in the brain of cirrhotic rats.

Main Methods:

• Rats underwent bile duct ligation (BDL) to induce cirrhosis.
• Monitored plasma and brain ammonia levels, liver injury markers, and locomotor function.
• Assessed brain tissue oxidative stress markers.

Main Results:

• BDL rats showed elevated plasma and brain ammonia, increased liver injury markers, and impaired locomotor activity.
• Cirrhotic rats exhibited increased brain oxidative stress markers.
• TAU supplementation (50-200 mg/kg) significantly reduced oxidative stress and improved locomotor activity.

Conclusions:

• Taurine (TAU) demonstrates potential as a protective agent against brain injury in liver cirrhosis.
• TAU supplementation may mitigate key pathological features of hepatic encephalopathy.
• Further research into TAU as a therapeutic for cirrhosis-associated neurological complications is warranted.